CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: A meta-analysis

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 287-303

  Zeng, Zhiyu ^a   Liu, Yanqiong ^a   Liu, Zhiming ^a   You, Jianpeng ^b   Chen, Zhiping ^b   Wang, Jian ^a   Peng, Qiliu ^a   Xie, Li ^a   Li, Ruolin ^a   Li, Shan ^a   Qin, Xue ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cytochrome P450 2D6; Meta analysis; Pharmacogenomics; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 2D6; TAMOXIFEN;

ADJUVANT THERAPY; ASIAN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2D6 GENE; DISEASE FREE SURVIVAL; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PUBLICATION BIAS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84880920061     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2195-9     Document Type: Review

References (61)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108 (Pubitemid 40372904)
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30
3. Fabian C, Tilzer L, Sternson L (1981) Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 2(4):381-390 (Pubitemid 12223758)
4. Dickschen K, Willmann S, Thelen K et al (2012) Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance. Front Pharmacol 3:92
5. Fleeman N, Martin Saborido C, Payne K et al (2011) The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess 15(33):1-102
6. Ingelman-Sundberg M, Sim SC, Gomez A et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496-526 (Pubitemid 350116943)
7. (EBCTCG) EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717 (Pubitemid 40719106)
8. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371-1388 (Pubitemid 28439961)
9. Xu Y, Sun Y, Yao L et al (2008) Association between CYP2D610 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19(8):1423-1429
10. Bijl MJ, van Schaik RH, Lammers LA et al (2009) The CYP2D64 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 118(1):125-130
11. Schroth W, Goetz MP, Hamann U et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13):1429-1436
12. Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8):1287-1293
13. Damodaran SE, Pradhan SC, Umamaheswaran G et al (2012) Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol 70(1):75-81
14. Sukasem C, Sirachainan E, Chamnanphon M et al (2012) Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev 13(9):4549-4553
15. Teh LK, Mohamed NI, Salleh MZ et al (2012) The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J 14(1):52-59
16. Goetz MP, Suman VJ, Hoskin TL et al (2013) CYP2D6 metabolism and patient outcome in the austrian breast and colorectal cancer study group trial (ABCSG) 8. Clin Cancer Res 19(2):500-507
17. Stingl JC, Parmar S, Huber-Wechselberger A et al (2010) Impact of CYP2D64 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin 26(11):2535-2542
18. Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23(36):9312-9318
19. Goetz MP, Knox SK, Suman VJ et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101(1):113-121 (Pubitemid 47555336)
20. Schroth W, Antoniadou L, Fritz P et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25(33):5187-5193 (Pubitemid 350232249)
21. Nowell SA, Ahn J, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91(3):249-258 (Pubitemid 40903087)
22. Wegman P, Elingarami S, Carstensen J et al (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9(1):R7 (Pubitemid 350215154)
23. Newman WG, Hadfield KD, Latif A et al (2008) Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14(18):5913-5918
24. Okishiro M, Taguchi T, Jin Kim S et al (2009) Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115(5):952-961
25. Abraham JE, Maranian MJ, Driver KE et al (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12(4):R64
26. Park HS, Choi JY, Lee MJ et al (2011) Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci 26(8):1007-1013
27. Lash TL, Cronin-Fenton D, Ahern TP et al (2011) CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 103(6):489-500
28. Thompson AM, Johnson A, Quinlan P et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279-287
29. Park IH, Ro J, Park S et al (2012) Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 131(2):455-461
30. Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(6):441-451
31. Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(6):452-460
32. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122(3):609-617
33. Jorde LB, Wooding SP (2004) Genetic variation, classification and 'race'. Nat Genet 36(11 Suppl):S28-S33
34. Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 39(2):91-92
35. Thakkinstian A, McElduff P, D'Este C et al (2005) A method for meta-analysis of molecular association studies. Stat Med 24(9):1291-1306 (Pubitemid 40585169)
36. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558 (Pubitemid 34746062)
37. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560 (Pubitemid 37088507)
38. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188 (Pubitemid 17189972)
39. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719-748
40. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634 (Pubitemid 27387172)
41. Copas J, Shi JQ (2000) Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1(3):247-262 (Pubitemid 33213534)
42. Toyama T, Yamashita H, Sugiura H et al (2009) No association between CYP2D610 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol 39(10):651-656
43. y Cajal TR, Altes A, Pare L et al (2010) Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 119(1):33-38
44. Lash TL, Cronin-Fenton D, Ahern TP et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49(3):305-312
45. Sirachainan E, Jaruhathai S, Trachu N et al (2012) CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenomics Pers Med 5:149-153
46. Dieudonne AS, Lambrechts D, Claes B et al (2009) Prevalent breast cancer patients with a homozygous mutant status for CYP2D64: response and biomarkers in tamoxifen users. Breast Cancer Res Treat 118(3):531-538
47. Rae JM, Sikora MJ, Henry NL et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9(4):258-264
48. Antunes MV, Linden R, Santos TV et al (2012) Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy. Ther Drug Monit 34(4):422-431
49. Wegman P, Vainikka L, Stal O et al (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7(3):R284-R290
50. Dunn BK, Greene MH, Kelley JM et al (2010) Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast cancer prevention trial. Int J Mol Epidemiol Genet 1(4):332-349
51. Goetz MP, Schaid DJ, Wickerham DL et al (2011) Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res 17(21):6944-6951
52. Serrano D, Lazzeroni M, Zambon CF et al (2011) Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian tamoxifen prevention trial. Pharmacogenomics J 11(2):100-107
53. Trojan A, Vergopoulos A, Breitenstein U et al (2013) CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. Cancer Chemother Pharmacol 71(2):301-306
54. Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al (2011) Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125(2):505-510
55. Schroth W, Hamann U, Fasching PA et al (2010) CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 16(17):4468-4477
56. Kiyotani K, Mushiroda T, Sasa M et al (2008) Impact of CYP2D610 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99(5):995-999 (Pubitemid 351997603)
57. Kiyotani K, Mushiroda T, Hosono N et al (2010) Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 20(9):565-568
58. Kiyotani K, Mushiroda T, Tsunoda T et al (2012) A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet 21(7):1665-1672
59. Yarnold J (2009) Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009. Clin Oncol 21(3):159-160
60. Ferraldeschi R, Howell SJ, Thompson AM et al (2010) Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol 28(29):e584-e585 author reply e586
61. Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509-518